Law360, New York (May 15, 2012, 12:47 PM ET) -- A European Union court has correctly fined AstraZeneca PLC €52.5 million ($62 million) for abusing its market dominance and the European patent system in order to block generic versions of ulcer drug Losec, an adviser to the court said Tuesday.
Advocate General Jan Mazak of the EU's Court of Justice found that AstraZeneca's appeal of the EU General Court's July 2010 decision — which trimmed the original European Commission's fine by €7.5 million — should be dismissed, saying AstraZeneca should not receive a further reduction of...
European Court Adviser Backs €53M AstraZeneca Antitrust Fine
To view the full article, take a free trial now.
